RhoVac strengthens management by appointing Anders Månsson as Chief Business Officer (CBO) and deputy CEO
Mar 08, 2019
RhoVac AB ("RhoVac") announces today, 8 March 2019, that the company recruits Anders Månsson as Chief Business Officer (CBO) and deputy CEO to lead the ongoing activities in business development.
The company has recruited Anders Månsson as Chief Business Officer (CBO) and deputy CEO to the management team, with responsibility for business development and communication. RhoVac strengthens the management team to ensure that the company has the right expertise and experience for the ongoing business development that is in parallel to further development of RhoVac's drug candidate RV001- treatment for metastatic cancer.
Anders Månsson holds a Bachelor of Science in Business Administration and Economics from Lund University and an MBA from the Business School Lausanne, Switzerland. Anders has long and solid experience in M&A, licensing and business development at a global level from LEO Pharma and Ferring Pharmaceuticals. In recent years, Anders has been on several positions including Industrial Advisor in Life Sciences to Ratos AB, Chairman of CanImGuide Therapeutics AB, board member of Respiratorius AB and EQL Pharma as well as CEO and partner of Longboat Amniotics.
Anders Månsson comments:
-With the drug candidate RV001 ready for clinical phase IIb, I see that RhoVac is now entering a stage where business development and partnerships will play an increasingly important role for the company's success. With my background and experience from this field, I therefore believe I can make a positive contribution to company's future development.
CEO Anders Ljungqvist comments:
-I look forward to the cooperation with Anders Månsson. Anders will strengthen and support the current management team’s profile by providing years of solid experience and expertise for the ongoing development of the company. A warm welcome to Anders from RhoVac!